Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

• Published in: Cancer research (Chicago, Ill.) Vol. 84; no. 10; pp. 1550 - 1559
• Main Authors: Shuptrine, Casey W, Chen, Yuhui, Miriyala, Jayalakshmi, Lenz, Karen, Moffett, Danielle, Nguyen, Thuy-Ai, Michaux, Jenn, Campbell, Kristen, Smith, Connor, Morra, Marc, Rivera-Molina, Yisel, Murr, Noah, Cooper, Sarah, McGuire, Ashlyn, Makani, Vishruti, Oien, Nathan, Zugates, Jeffery T, de Silva, Suresh, Schreiber, Taylor H, de Picciotto, Seymour, Fromm, George
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 15.05.2024
• Subjects: Animals; Biological Agents & Therapies; Cancer Vaccines - administration & dosage; Cancer Vaccines - genetics; Cancer Vaccines - immunology; Carcinogenesis; Cell Line, Tumor; Female; Humans; Immunology; Immunotherapy; Lipids - chemistry; Mice; Mice, Inbred C57BL; Nanoparticles - chemistry; Priority Report; Receptors, Immunologic - genetics; Receptors, Immunologic - immunology; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; RNA, Messenger - genetics
• DOI: 10.1158/0008-5472.CAN-23-2875
• ISSN: 0008-5472

Lipid nanoparticle (LNP)-encapsulated mRNA has been used for in vivo production of several secreted protein classes, such as IgG, and has enabled the development of personalized vaccines in oncology. Establishing the feasibility of delivering complex multispecific modalities that require higher-order structures important for their function could help expand the use of mRNA/LNP biologic formulations. Here, we evaluated whether in vivo administration of mRNA/LNP formulations of SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT could achieve oligomerization and extend exposure, on-target activity, and antitumor responses comparable with that of the corresponding recombinant fusion proteins. Intravenous infusion of the formulated LNP-encapsulated mRNAs led to rapid and sustained production of functional hexameric proteins in vivo, which increased the overall exposure relative to the recombinant protein controls by ∼28 to 140 fold over 96 hours. High concentrations of the mRNA-encoded proteins were also observed in secondary lymphoid organs and within implanted tumors, with protein concentrations in tumors up to 134-fold greater than with the recombinant protein controls 24 hours after treatment. In addition, SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT mRNAs induced a greater increase in antigen-specific CD8+ T cells in the tumors. These mRNA/LNP formulations were well tolerated and led to a rapid increase in serum and intratumoral IL2, delayed tumor growth, extended survival, and outperformed the activities of benchmark mAb controls. Furthermore, the mRNA/LNPs demonstrated improved efficacy in combination with anti-PD-L1 relative to the recombinant fusion proteins. These data support the delivery of complex oligomeric biologics as mRNA/LNP formulations, where high therapeutic expression and exposure could translate into improved patient outcomes. Lipid nanoparticle-encapsulated mRNA can efficiently encode complex fusion proteins encompassing immune checkpoint blockers and costimulators that functionally oligomerize in vivo with extended pharmacokinetics and durable exposure to induce potent antitumor immunity.